ACT enters into a contract with U of L Professor to Advance Research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Endo Announces Peyronie’s Disease Presentation at...

Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today...

Leadership at NHS Hospitals in Leeds...

A watchdog has gone on to say that the...

Developing Dr. CaBot, A Medical Education...

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for...

The medicines regulator of the UK has announced plans...

Advanced Cancer Therapeutics LLC (ACT) entered into a contract with the University of Louisville’s Dr. John Trent as part of its effort to company move potential cancer treatments toward clinical studies.

Trent is an associate professor in the Department of Medicine at U of L’s James Graham Brown Cancer Center. Advanced Cancer Therapeutics, or ACT, works closely with researchers at the cancer center to get cancer treatments to market more quickly.

ACT has identified as top priorities two compound programs it has licensed from U of L related to the growth of cancer cells. The firm also has designed and synthesized more than 200 small-molecule compounds against cancer targets in both programs, according to a news release.

“With the use of computers, Will work closely with medicinal chemists, helping to identify the most potent compounds before moving forward with additional studies. Toxicology studies could cost up to $1 million for each of ACT’s two top programs” said Trent.

“ACT is pleased to be working with Dr. Trent as we collaborate to accelerate the discovery process to develop potentially lifesaving therapeutics for cancer patients,” Riggs said in the release.

Latest stories

Related stories

Developing Dr. CaBot, A Medical Education Tool That Reasons

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for Medtech Regulatory Reforms

The medicines regulator of the UK has announced plans...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »